Ropes & Gray Advises Apollo Therapeutics on Exclusive Ex-China License for Clinical-Stage FGF21/GLP-1 Dual Receptor Agonist
November 13, 2024
November 13, 2024
BOSTON, Massachusetts, Nov. 13 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Apollo Therapeutics in a licensing agreement with Sunshine Lake Pharma Co., Ltd., a member of China's HEC Group, pursuant to which Apollo Therapeutics will receive exclusive ex-China rights to develop and commercialize HEC88473, a clinical-stage FGF21/GLP-1 dual receptor agonist developed by Sunshine Lake that has potential in multiple disease areas. The transaction was . . .
Ropes & Gray advised Apollo Therapeutics in a licensing agreement with Sunshine Lake Pharma Co., Ltd., a member of China's HEC Group, pursuant to which Apollo Therapeutics will receive exclusive ex-China rights to develop and commercialize HEC88473, a clinical-stage FGF21/GLP-1 dual receptor agonist developed by Sunshine Lake that has potential in multiple disease areas. The transaction was . . .